

# Syngene

Ref: Syn/CS/SE/IP/2026-27/Apr/10

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 & 3,  
Bommasandra Industrial Area, IV Phase,  
Jigani Link Road, Bengaluru 560099,  
Karnataka, India.  
T +91 80 6891 9191  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

April 30, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and year ended March 31, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors.

The above-mentioned Investor Presentation will also be available on the website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Chethan Yogesh  
**Company Secretary and Compliance Officer**

**Enclosed:** Investor Presentation.

**Syngene**

Putting Science to Work

# Investor Presentation

April 2026



## Safe harbour



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



# Contents

**1**

**Q4 FY26 Highlights**

**2**

**Syngene – Putting Science to Work**

**3**

**Syngene strengths**

**4**

**Financials**

**5**

**Shareholding and Share Information**



**1**

**Q4 FY26 Highlights**



# Q4 and FY26 performance

## Operating Highlights

- **ADC Platform Expansion:** Commenced operations at the ADC discovery laboratory during the quarter, complementing the recently added GMP bioconjugation suite and establishing end-to-end ADC capabilities from discovery to manufacturing
- **Quality & Regulatory:** Completed 14 audits during the quarter (FY total: 85) and obtained Good Clinical Practice – National Accreditation Board for Testing and Calibration Laboratories (GCP-NABL) accreditation, reinforcing adherence to globally recognized standards for clinical research and data quality
- **Sustainability & ESG:** Included in the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and top 9% globally; also recognised as an ‘Industry Mover’ for the highest year-on-year improvement in its Corporate Sustainability Assessment score
- **Key management changes:**
  - Kiran Mazumdar-Shaw transitioned from Non-Executive Chairperson to Executive Chairperson, effective 1 April 2026, for a five-year term
  - Siddharth Mittal appointed Managing Director & Chief Executive Officer, effective 1 July 2026, succeeding Peter Bains. He joins from Biocon Limited, where he served as Managing Director and CEO
  - Maninder Kapoor Puri appointed Chief Human Resources Officer and Executive Committee member, effective 1 May 2026, and Abhijit Zutshi appointed Chief Commercial Officer and Executive Committee member, effective 1 May 2026; both previously held leadership roles at Biocon

## Q4 FY26 Financial Highlights

### Revenue from Operations

Rs 1,037 Cr ( 2% Y-o-Y)  
~USD 112 Mn

### Operating EBITDA margin

29% (34% in Q4 FY25)

**PAT before exceptional items : Rs. 153 Cr (-16%YoY)**

## FY26 Financial Highlights

### Revenue from Operations

Rs 3,739 Cr ( 3% Y-o-Y)  
~USD 419 Mn

### Operating EBITDA margin

25% (29% in FY25)

**PAT before exceptional items : Rs. 380 Cr ( -20% YoY)**

2

Syngene – Putting Science to Work



# Partner in innovation: #Putting Science to Work

## Who we are and what we do

*We aim to be a world class partner delivering innovative scientific solutions for clients*



*We offer integrated solutions across research, development and manufacturing*



*Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals*




*Our team includes more than ~5,700+ scientists out of total 8,300+ headcount, operating across 4 global state-of-the-art campuses located in India's leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore)*



*Established track record in discovery research and development/ manufacturing for small and large molecules*

# Our journey so far



# Key facts and figures



**~400**  
active clients



**16** out of top **20**  
pharma companies are  
clients



**400+**  
patents  
held with clients



## World class infrastructure

International presence with global campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards



**Rs. 3,739 Cr**  
(~US\$419 Mn)  
FY26 Revenue from  
operations



**Rs. 380 Cr\*\***  
FY26 PAT



**8,373** headcount  
including **5,778**  
talented scientists



**92%**  
energy from  
renewable sources\*



All figures are as on March 31, 2026 / FY2026, unless otherwise specified

\*As on March 31, 2025


\*\*before exceptional items

# Syngene – one of the largest integrated CRDMO players in India

One-stop platform for integrated drug discovery, development and manufacturing across modalities

## Expanding capacity

(in Million sq. ft.)




**More than tripled the infrastructure that is qualified to meet international standards**

- Expanded laboratory capacity in Bangalore and Hyderabad
- Expanded to Mangalore for commercial API manufacturing
- Acquired land in Hyderabad for long term growth in research business
- Acquired multi-modal biologics facility from Stelis Biopharma Ltd
- Acquired first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC
- US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities

## Building capabilities for future

(#)




**Over 2.5x employees from FY16 comprising talented scientists**

- ~5,700+ scientists comprising PhDs, MS
- Skills and experience to become trusted thought partner in cutting-edge research
- Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
- Proven success in delivering integrated CMC programs and clinical candidates

## Building partnerships

(#)



**Over 50% increase in active clients**

**16 out of top 20 pharma companies are clients**

- Expanded partnerships with big pharma and emerging biopharma
- Expanded into commercial manufacturing in Biologics with Zoetis
- Enhanced BD presence across key value clusters including US and Europe
- 25-year strategic partnership with BMS – established BBRC, India's first and largest dedicated R&D center

# 3-pronged growth strategy across diversified platform

## Research Services (CRO)

### Discovery Services



**Flexible Platform** with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

**SynVent** - proprietary platform for Integrated Drug Discovery

**SARchitect**- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies

### Dedicated R&D Centers



**Ring-fenced** infrastructure for exclusive operations for an individual client

**Dedicated** multi-disciplinary team of scientists

**Access** to entire Syngene ecosystem for specialist research and development operations

### T&CR



Comprehensive research services through trials conducted on both healthy volunteers and patients

- Human Pharmacology Unit (Phase I/BE studies)
- Clinical Trial Services – full solution provider for conducting global trials
- Translational services- a continuum from preclinical to clinical trials
- Regulated bioanalysis for large and small molecules
- Central Laboratory

## Large Molecule CDMO



Process development

Manufacturing of large molecules for clinical/commercial supplies

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant facilities

State-of-the art Biologics manufacturing facilities with international presence

## Small Molecule CDMO



Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing of small molecules for commercial supplies

State-of-the art API manufacturing facility

# Our Strategy



## Research Services

Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre-clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.



## Development and Manufacturing Services – Large Molecules

Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.



## Development and Manufacturing Services – Small Molecules

Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider



## Operational Excellence

Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction.



## People

Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation



## Environmental, Social and Governance (ESG)

Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations

# 3

## Syngene strengths



# Syngene strengths

## A global scale CRDMO player

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



## Solutions through innovation

- IP fully assigned to clients
- Track record of data management and security
- Over 400+ patent filings by clients recognizing Syngene scientists



## Quality matters

- Fully digitized quality organization
- Strong compliance track record with global regulators
- US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities
- 85 client and regulator audits in the last financial year



## Science in our DNA

- Global presence : India life science hubs: Bangalore, Mangalore and Hyderabad & Baltimore, USA
- ~5700+ qualified scientists including ~500 PhDs (8,300+ total headcount)
- Resilient supply chain management
- 3 Mn+ sq. ft world-class R&D and manufacturing infrastructure



## Blue chip client list

- ~400 active clients
- Partnering with large / mid-size / emerging biopharma and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors



## Making a difference

- Partnerships have delivered numerous clinical candidates
- Delivery history for integrated CMC programs up to clinical trials and beyond



# Experienced workforce: building capabilities and careers

**8,373** total headcount

**5,778** scientists delivering high quality solutions – create a competitive edge

**7%** PHDs

## Inspiring technical excellence and providing opportunities to grow

### Empowering our workforce

- **Thrive360 operating philosophy** embedding wellbeing into how work is designed and delivered - supporting physical, mental & emotional, social, financial and career wellbeing
- **Future-focused performance and career conversations** that build capability, clarify growth pathways and strengthen engagement and retention

### Continuous learning & development

- **Enterprise-wide leadership and manager capability development** to build strong people leadership and succession depth
- **Scientific skills development** to standardise and advance scientific and technical upskilling across the organization
- Supporting **talent stability and execution** continuity during a demanding operating environment

### Shaping a culture of belonging

- **Inclusive culture** broadening access to scientific and leadership talent
- **Diverse teams** strengthening innovation and problem-solving
- **27%** women representation overall and **19%** women in senior management

All figures are as on March 31, 2026

# Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs

## HQ campus at Bangalore, India

90 Acres where most of Syngene's capabilities are housed today



**Biologics**  
Discovery development & and manufacturing plants in Bangalore, India

## Fully functional R&D Centre at Genome Valley, Hyderabad, India

Genome Valley, Hyderabad, India



**API manufacturing**  
Commercial manufacturing to support product launch located at Mangalore, India

## USA based Biologics facility

Bayview, Baltimore, USA



# We currently operate a range of successful collaboration models




## Dedicated R&D Labs

- Customers receive ring-fenced infrastructure customized to their research needs
- Dedicated scientific and support teams work exclusively on the customer's projects
- Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation



## Full time equivalent (FTE)

- A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer's projects
- Deliverables and team composition evolve as the project progresses to align with changing requirements
- Agreements are typically renewed annually, ensuring continuity and flexibility



## Fee For service (FFS)

- Services are provided within a defined scope
- Flexible, on-demand personnel and research infrastructure are allocated to meet project objectives
- Engagements can be short-term or long-term, based on project requirements



## Risk / Reward Model

- A milestone-driven approach covering a portfolio of research projects
- Customers benefit from reduced upfront costs, with payments tied to predefined success milestones



## Outcome – based model with Service Level Agreement

- A contract structured around the achievement of predefined outcomes
- Linked to specific productivity goals to ensure performance-driven results

... and are open to any single or combination of above

# Our experience spans multiple industry segments and partners us with global leaders across the world...

The infographic displays six industry segments, each with a list of partner logos and a representative icon:

- Large & Mid-Sized BioPharma:** Bristol Myers Squibb, GSK, sanofi, NOVARTIS, AMGEN, MERCK, Boehringer Ingelheim, Baxter. Icon: Hospital building.
- Emerging BioPharma (EBP):** Albireo (AN IPSEN COMPANY), AMPHISTA THERAPEUTICS, Genmab, ASCENEURON, PharmAust LIMITED, saniona, C4 Therapeutics. Icon: Interlocking puzzle pieces.
- Animal Health:** IVAOES ANIMAL HEALTH, Phibro ANIMAL HEALTH CORPORATION, zoetis, Elanco, MERCK Animal Health. Icon: Paw print with a plus sign.
- AgroChem:** FMC, Dow AgroSciences. Icon: Erlenmeyer flask with a plant growing inside.
- CPG:** Givaudan, PURINA. Icon: Industrial factory with a scale.
- Chemicals/Polymers:** Essilor, Beiersdorf, KRATON. Icon: Chemical molecular structure.

# Operational robustness driving strategy execution

## Continuous improvement embedded through a structured Lean Six Sigma framework


Certification pathway from White Belt to Master Black Belt  
90+ Green Belts and 60+ Black Belts driving operational excellence  
10+ Master Black Belts anchoring enterprise-level transformation

## Quality management system: digitized and audit-ready

85 customer and regulator audits in the last FY  
6 successful USFDA audits in the last 5 years

## Client-focused commercial organization

Leaders based in the US, Europe, UK and Asia close to client locations



## Focused execution through strong Project Management

Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects

## Digital as a differentiator

AI capability in all research teams  
Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance

## Strategic Sourcing that makes a difference


Effective global collaboration with 2,800+ suppliers across 30 countries

Building a resilient supply chain amid geopolitical uncertainty through robust logistics network, dual sourcing strategy, and domestic supplier development for critical raw materials.

# Syngene digital initiatives aimed at driving innovation and operational

At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.

Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements



# Committed to safety and sustainability

## Safety is our first priority

- Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
- Risk assessments are an integral part of our operation
- Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
- Lost time injury frequency rate (LTIFR ): 0.00
- 36,737 hours of EHSS training



Proud to be recognized by TIME Magazine and Statista as:

- **World's Most Sustainable Companies 2025**
- **World's Best Companies in Sustainable Growth 2026**

## ESG Rating Performance

ESG Rating Agency	FY25	FY24	FY23
EcoVadis	Silver (91 <sup>st</sup> percentile)	Silver (86 <sup>th</sup> percentile)	Bronze (65 <sup>th</sup> percentile)
CDP	B (Water Security) B (Climate Change)	B (Water Security) B (Climate Change)	D (Water Security) C (Climate Change)
Sustainalytics	14.7 Low Risk	15.6 Low Risk	12.4 Low Risk
MSCI	A	BB	BBB
DJSI	76	50	N/A

## Committed to environmental protection

- Committed to Science-based targets for greenhouse gases
- 95% of total hazardous and non-hazardous waste recycled
- 92% of energy procured from renewable energy sources
- 1,296 MT equivalent CO2 savings from energy conservation
- 73,313 tCO2e of GHG emissions avoided
- 64% YoY freshwater savings achieved
- 1,04,413 KL fresh water saved from recycling, reusing and rainwater harvesting
- 11,433 KL rainwater harvested

# Accreditations



- USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities.
- GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory
- GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment
- USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility
- ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility
- ISO 9001:2015, 14001:2015, 45001:2018, ISO 13485:2016, ISO 50001:2018 and ISO/IEC 27001:2022 accreditations.



# We have consistently received industry recognition for our scientific capability and business excellence

- **CMO Leadership Awards 2022** Presented by Life Science Leader and Outsourced Pharma
- **CMO Leadership Award Champion 2022** - Presented by Life Science Leader and Outsourced Pharma
- **Golden Peacock Award for Excellence in Corporate Governance** for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Unique or Innovative Leadership Program' and 'Best Advance in Compliance Training'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for
- **Asia Pacific Biologics CMO Excellence Awards 2022** - For Quality
- **Biopharma Honours Award 2022** - For Viral Testing Facility by Informa Markets
- **Most Preferred Workplace 2022** - Award by MarksmenDaily.com

- **EcoVadis Sustainability Rating, 2024** : Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide.
- **Asia Pacific Biologics CMO Excellence Awards 2024** : Adjudged Best Biologics CMO in South Asia by IMAPAC
- Winner under the Reliability and Compatibility categories for exceeding customer expectations at **CDMO Leadership Awards 2024**
- Declared champion by the Institute of Supply Chain Management (ISCM) at the **Pharma Supply Chain Management 5.0 summit**.
- Award for Excellence in Environment Health and Safety (EHS) practices at **CII-SR EHS Excellence Awards 2023**
- Awarded **India's Best Managed Company** by Deloitte
- **Golden Peacock Award 2023**: For risk management practices under the Pharmaceutical sector category.
- **Best Overall Sustainable Performance (Pharmaceutical) 2023** at the 2nd Edition India Sustainability Conclave & Awards 2023



2021

2022

2023

2024

2025-2026

- **Dream Companies to Work Award** at the 29<sup>th</sup> Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma** - for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence— Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Best Corporate Foundation Award** at the World CSR Congress

- **Golden Peacock National Quality Award 2023** For meeting the overall requirements of the Golden Peacock Excellence Model
- **Biopharma Excellence Awards 2023** For Best Contract Development and Manufacturing Organization (CDMO)

- **CDMO Leadership Award 2025**: Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect.
- **Biopharma Excellence Awards 2025 (India Edition)**: Adjudged Best Bioprocessing Supplier – Analytical Services by IMAPAC.
- **Pharma Supply Chain Champion 2025**: Ranked #1 among mid-sized pharma and API firms by the Institute of Supply Chain Management (ISCM).
- **TIME Magazine & Statista – World's Most Sustainable Companies 2026**: Ranked amongst the global top three and #1 in India in the Pharma & Biotech category; second recognition in six months.
- **S&P Global Sustainability Yearbook 2026**: Ranked among the top 10 life sciences companies and the top 9% globally; recognised as an 'Industry Mover' for or achieving the highest year-on-year improvement in its Corporate Sustainability Assessment score.
- **NAMC Gold Award**: Biologics Manufacturing Excellence at the National Awards for Manufacturing Competitiveness (NAMC).
- **Achieved My Green Lab 'Green Certification' (>94% score)** for laboratories
- **EcoVadis 2025 score** improved to 74/100, placing Syngene in the 91st percentile globally.

# Syngene has established an enterprise-wide risk oversight with clear accountability from management to the Board

*Syngene's enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance*



4

Financials



# Q4 FY26 financial highlights

All figures in Rs. Mn unless otherwise specified

Particulars	Q4 FY26	Q4 FY25	YoY change	Q3 FY26	QoQ change
<b>Revenue from operations</b>	<b>10,365</b>	<b>10,180</b>	<b>2%</b>	<b>9,171</b>	<b>13%</b>
Other income	222	189	17.5%	154	44%
<b>Reported revenue</b>	<b>10,587</b>	<b>10,369</b>	<b>2%</b>	<b>9,325</b>	<b>14%</b>
Material costs	2,331	2,350	-1%	2,299	1%
Staff costs	3,316	2,794	19%	2,992	11%
Other direct costs	260	221	17%	258	1%
Other expenses	1,216	1,333	-9%	1,297	-6%
Foreign exchange (gain)/loss, net	209	46	354%	233	-10%
<b>EBITDA</b>	<b>3,256</b>	<b>3,625</b>	<b>-10%</b>	<b>2,246</b>	<b>45%</b>
<b>EBITDA Margin</b>	<b>30.8%</b>	<b>35.0%</b>		<b>24.1%</b>	
Depreciation and Finance Cost	1,115	1,061	5%	1,256	-11%
<b>PBT</b>	<b>2,020</b>	<b>2,405</b>	<b>-16%</b>	<b>990</b>	<b>104%</b>
Tax	488	572	-15%	261	87%
<b>PAT before exceptional items</b>	<b>1,532<sup>(3)</sup></b>	<b>1,833</b>	<b>-16%</b>	<b>729</b>	<b>110%</b>
<b>PAT Margin</b>	<b>14.5%</b>	<b>17.7%</b>		<b>7.8%</b>	
<b>PAT after exceptional items</b>	<b>1,479</b>	<b>1,833</b>	<b>-19%</b>	<b>150</b>	<b>886%</b>

(1) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity

(2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

(3) Excludes (i) a gratuity re measurement credit of Rs. 20 Cr. (net of tax) arising from revised labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.

## Balance Sheet Highlights

As on 31<sup>st</sup> March 2026

All figures in Rs. Mn unless otherwise specified

<b>Shareholders' funds</b>	<b>48,391</b>
Net Fixed assets	40,456
Other net assets <sup>(1)</sup>	-10,068
Net cash/(debt) <sup>(2)</sup>	18,003
<b>Total Use of Funds</b>	<b>48,391</b>

# FY26 financial highlights

All figures in Rs. Mn unless otherwise specified

Particulars	FY26	FY25	YoY change
<b>Revenue from operations</b>	<b>37,387</b>	<b>36,424</b>	<b>3%</b>
Other income	707	718	-1%
<b>Reported revenue</b>	<b>38,094</b>	<b>37,142</b>	<b>3%</b>
Material costs	9,186	9,425	-3%
Staff costs	12,297	10,792	14%
Other direct costs	1,029	970	6%
Other expenses	5,082	4,800	6%
Foreign exchange (gain)/loss, net	609	19	3104%
<b>EBITDA</b>	<b>9,891</b>	<b>11,136</b>	<b>-11%</b>
<b>EBITDA Margin</b>	<b>26.0%</b>	<b>30.0%</b>	
Depreciation and Finance Cost	4,529	4,326	5%
<b>PBT</b>	<b>4,875</b>	<b>6,279</b>	<b>-22%</b>
Tax	1,076	1,530	-30%
<b>PAT before exceptional items</b>	<b>3,799<sup>(1)</sup></b>	<b>4,749<sup>(2)</sup></b>	<b>-20%</b>
<b>PAT Margin</b>	<b>10.0%</b>	<b>12.8%</b>	
<b>PAT after exceptional items</b>	<b>3,167</b>	<b>4,962</b>	<b>-36%</b>

(1) Excludes (i) impact of Rs. 38 Cr. (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.

(2) Excludes an exceptional item of Rs 21 Cr. (net of tax) relating to the final settlement from an insurance claim.

# 5

## Shareholding and Share Information



# Syngene and Biocon Group

## Syngene

**Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services**




**Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene**

**Syngene**

### **Integrated services:**

- Research Services
- Development and for
- Manufacturing small/large molecules




- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs



# Shareholding and Share Information

## Syngene's shareholders\*



## Syngene's Share Information\*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Mn)	1,57,106
% free-float <sup>^</sup>	47%
Free-float market cap (Rs. Mn)	74,337
Share Outstanding (Mn)	403

## For more details

Visit our website [www.syngeneintl.com](http://www.syngeneintl.com)



<https://www.linkedin.com/company/syngene-international-limited>



<https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkBIQ>

IR Contact:

**Nandini Agarwal**

[investor@syngeneintl.com](mailto:investor@syngeneintl.com)

[nandini.agarwal@syngeneintl.com](mailto:nandini.agarwal@syngeneintl.com)

Media Contact:

**Vijay Jeevanandham**

E: [\\_Vijay.jeevanandham@syngeneintl.com](mailto:_Vijay.jeevanandham@syngeneintl.com)

